Myrexis Inc.

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

Role: collaborator

Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine

Role: collaborator

R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence

Role: lead

Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme

Role: lead

Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme

Role: lead

Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments

Role: lead

Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme

Role: lead

Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma

Role: lead

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

Role: lead

A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days

Role: lead

Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*

Role: lead

Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.

Role: lead

Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

Role: lead

Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

Role: lead

Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol

Role: lead

Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

Role: lead

Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases

Role: lead